Trialysis Length

During a recent shift, Dr. Waters asked me “can I use a the 15cm trialysis line in the femoral vein?” To which I replied “I don’t see why not.” That got me thinking, is there a reason why not? We do have two length catheters after all (15cm and 24cm). Low and behold there is a reason why not to use the shorter length trialysis catheter there. The reason is that the catheter will not make it past the lumen of the common iliac vein and into the IVC where it is recommended the end of the catheter sit. CVCs pose certain risks such as CRBSIs, DVTs, and vessel stenosis. There are even case reports of vessel erosion happening when a catheter sits in the iliac and not in the IVC.

Bottom line; use the right size kit for the appropriate vessel, like Dr. Waters eventually did! The rest of this post is an overview on trialysis catheter placement.

Trialysis catheter placement in the emergent setting is a procedure undertaken to quickly establish vascular access for hemodialysis in critically ill patients with acute kidney injury or end-stage renal disease. This intervention becomes necessary when traditional vascular access methods, such as peripheral intravenous catheters or arteriovenous fistulas, are not feasible or fail to provide adequate blood flow for dialysis.

Indications:

Urgent Hemodialysis: In cases of severe acute kidney injury or end-stage renal disease, where immediate initiation of hemodialysis is required. “AEIOU” acidosis, refractory hyperkalemia, ingestion of certain substances (methanol, ethylene glycol, lithium, salicylates), overload of volume refractory to medical management, and uremia.

Contraindications:

  1. Vascular Anomalies or Injuries: Presence of significant vascular anomalies or injuries at the potential catheter insertion site.

  2. Local Infections: Infection at the proposed catheter insertion site.

  3. Severe Coagulopathy: Placement may be contraindicated in patients with uncontrolled bleeding disorders. (Relative contraindication – should use more compressible sites like the femoral vein)

Equipment Needed:

  1. Trialysis Catheter Kit: Includes the catheter, guidewires, dilators, and sheaths.

  2. Ultrasound Machine: To assist in locating suitable veins and ensuring proper catheter placement.

  3. Sterile Drapes and Gloves: To maintain aseptic conditions during the procedure.

  4. Local Anesthetic Agents: For numbing the catheter insertion site.

  5. Syringes and Needles: For administration of local anesthetic agents and other medications as needed.

  6. Suture and Dressing Materials: For securing the catheter in place and maintaining a sterile environment post-placement.

Procedure:

  1. Patient Assessment: Evaluate the patient's clinical status, coagulation profile, and vascular anatomy to determine the most appropriate site for catheter placement.

  2. Informed Consent: Obtain informed consent from the patient or their legal representative, explaining the risks and benefits of the procedure.

  3. Preparation: Position the patient appropriately, and ensure sterile conditions using drapes and gloves.

  4. Local Anesthesia: Administer local anesthesia at the proposed catheter insertion site.

  5. Ultrasound Guidance: Use ultrasound to locate a suitable vein and guide the catheter insertion, ensuring proper placement.

  6. Needle placement: With a needle attached to a syringe, insert the needle and begin withdrawing on the syringe while progressing, both to see when blood returns, and to ensure no introduction of air bubbles. Needles should be at a 45 degree angle when inserted. Preferably there is ultrasound visualization of the needle inside the lumen of the vessel.

  7. Guidewire insertion: Remove the syringe from the needle and progress the guidewire. This should be able to occur smoothly. If it is not progressing smoothly, you may need to drop the angle of the needle, as the guidewire may be getting forced against the backwall of the vessel. The wire should only go in about 20cm.

  8. Confirmation of guidewire: Ultrasound visualization should be done to confirm the guidewire. Never assume the guidewire is in the right spot. Know it is, by seeing it is. This should be done in both short plane and longitudinal plane.

  9. Incision: Incise at the site of the guidewire to be able to dilate and place catheter.

  10. Dilate (twice): The trialysis catheter requires double dilation given how large the catheter is. Place the dilator over the guidewire (without letting go of the wire). Go approximately halfway down the dilator, remove the dilator, and then repeat with the next dilator. (Be mentally prepared for a fair amount of blood).

  11. Catheter Insertion: Introduce the catheter through the dilated tract, securing it in place using sutures.

  12. Confirmation: Confirm proper catheter placement using imaging techniques such as fluoroscopy or ultrasound.

  13. Post-Procedure Care: Apply a sterile dressing, monitor for any complications, and secure the catheter to prevent accidental dislodgement.

Sources:

  1. National Kidney Foundation. (2006). "Clinical Practice Guidelines for Vascular Access." Retrieved from https://www.kidney.org/sites/default/files/docs/12-50-0210_jag_dcp_guidelines-va_oct06_sectiona_ofc.pdf

  2. American Society of Nephrology. (2006). "Clinical Practice Guidelines for Hemodialysis Adequacy, Update 2006." Retrieved from https://www.kidney.org/sites/default/files/docs/12-50-0900_anemiaworkbook_upd-0926.pdf

 · 

POTD: Wegovy and Ozempic

 ·   · 

GLP-1 class medications have recently grown in popularity. Two of the most popular GLP medications today, Wegovy and Ozempic, both have semaglutide as their active ingredient. They have come into the limelight after a large double-blinded study published in NEJM, showed an average 14.9% decrease in weight in obese patients given semaglutide on top of lifestyle modifications, compared to 2.4% in the control arm (see research summary at end). It should be noted that this study was funded by Novo Nordisk, the pharmaceutical company that produces semaglutide. Coincidentally, Novo Nordisk’s stock valuation has tripled over the last 2 years since the release of the study.  


What are GLP-1 agonists?

GLPs were first hinted at in the 1960s, when scientists using radioimmunoassays to study glucagon formation in the pancreas unexpectedly saw elevated activity in the intestines during their surveys. Over the next decade, gut proteins were isolated and found to have 50% sequence similarity to glucagon, and these proteins were termed glucagon-like peptides 1 and 2 (GLP-1 & 2)1. Further studies suggested that GLP-1 stimulates both synthesis and secretion of insulin via multiple cAMP-dependent pathways.

Of significance to today’s popularity is evidence of GLP-1 mediated suppression of appetite via CNS targets1. Other interesting findings of GLP-1 suggest possible cardioprotective characteristics. Animal studies showed increased myocardiocyte glucose uptake and decreased reperfusion injury in dogs and rodents induced to have MI despite controlling for weight1.

Today, GLPs can be generally classified into 2 categories – long acting (administered once weekly) or short acting (administered daily), though most remain approved only for treatment of DM. In addition to semaglutide, another GLP-1 obtaining FDA approval for weight loss includes tirezepatide (Zepbound)2.

What are the adverse effects I need to be aware of?

Although GLP-1 class medications have been on the market for 2 decades now, rarer serious side effects are now being seen more simply due to recent increases in the number of people on these medications3. One effect that may impact emergency medicine interventions is GLP-1 induced delay in gastric emptying, increasing risk of aspiration in patients with airway compromise. Though the absolute risk of GLP-1 related aspiration during intubation is still low, case studies of large volume emesis in patients who fasted 20 hours have been concerning enough to prompt the American Society of Anesthesiology to issue a guidance suggesting holding GLP-1 agonists prior to elective intubations4,5.

Other serious adverse effects of GLP-1 include 9x increased risk of pancreatitis, 4x increased risk of bowel obstruction, 3x increased risk of gastroparesis, though again the absolute risk of all these events were still < 1% per year.

Do I need to be worried about hypoglycemic events?

GLP-1s do not usually cause hypoglycemia, unless combined with another agent/therapy that is associated with hypoglycemia such as sulfonylureas or insulin injections6,7.

How accessible is semaglutide?

In short, not very. Current demand for the mediation is outpacing production. Novo Nordisk has reported they have run out of stock of Wegovy 1.7mg for the month of December and anticipate possible disruptions of related GLP-1 liraglutide supply8. Wegovy’s demand has crept into increased off-label prescriptions of Ozempic, reducing access for patients with diabetes9. Current prices on GoodRx show $900/month for Ozempic and $1400/month for Wegovy.

References

  1. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010

  2. FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration. Accessed December 26, 2023. https://content.govdelivery.com/accounts/USFDA/bulletins/37a0d49

  3. Ruder K. As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging. JAMA. 2023;330(22):2140-2142. doi:10.1001/jama.2023.16620

  4. Gulak MA, Murphy P. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. Can J Anaesth J Can Anesth. 2023;70(8):1397-1400. doi:10.1007/s12630-023-02521-3

  5. Patients Taking Popular Medications for Diabetes and Weight Loss Should Stop Before Elective Surgery, ASA Suggests. Accessed December 26, 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/patients-taking-popular-medications-for-diabetes-and-weight-loss-should-stop-before-elective-surgery

  6. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors. Diabetes Obes Metab. 2016;18(3):203-216. doi:10.1111/dom.12591

  7. Suran M. As Ozempic’s Popularity Soars, Here’s What to Know About Semaglutide and Weight Loss. JAMA. 2023;329(19):1627-1629. doi:10.1001/jama.2023.2438

  8. Supply update. Novo Nordisk. Accessed December 26, 2023. https://www.novonordisk-us.com/content/nncorp/us/en.html

  9. McPhillips D. CNN Exclusive: Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients. CNN. Published September 27, 2023. Accessed December 26, 2023. https://www.cnn.com/2023/09/27/health/semaglutide-equitable-access/index.html

 · 

Marine Toxins

Ciguatera:

Background:

 

Ciguatera is a type of food poisoning caused by consuming fish that have accumulated a heat-stable toxin produced by dinoflagellates. The toxins, known as ciguatoxins, primarily concentrate in large predatory reef fish in tropical and subtropical waters.

Clinical Manifestations:

 

Symptoms include gastrointestinal issues 3-30 hours after consumption (nausea, vomiting, diarrhea), neurological effects (numbness, tingling, temperature reversal***), and cardiovascular manifestations (bradycardia, hypotension). Neuro symptoms may last for weeks or even months (up to 2% of people have this for years).

***the one time I had a patient I thought may have ciguatera, my dumb a** was at the bedside with a bag of ice on their leg, asking this person if they thought it was hot or cold. They looked at me blankly and told me it was cold….

 

Clinical Management:

 

There is no specific antidote for ciguatera. Treatment focuses on supportive care, including intravenous fluids for dehydration and medications to alleviate symptoms such as pain and nausea. Amitriptyline and gabapentin are often used for neuro symptoms.

There is note of mannitol use for neuro symptoms if used in the first two days, but showed no benefit over saline in a RCT.

 

Clinical Disposition:

 

Most patients are discharged.

 

Scombroid Poisoning:

Background:

 

Scombroid poisoning results from the ingestion of improperly handled or spoiled fish, particularly histidine-rich fish like tuna, mackerel, and mahi-mahi. Bacterial decarboxylation of histidine leads to the formation of histamine. Most common in Hawaii and Florida.

Clinical Manifestations:

 

Symptoms mimic allergic reactions and include flushing, headache, palpitations, and gastrointestinal distress.

 

Clinical Management:

 

Treatment involves antihistamines to alleviate symptoms. In severe cases, epinephrine may be required. Albuterol can be used in cases of respiratory distress.

 

Clinical Disposition:

 

Typically patients are discharged.

 

Tetrodotoxin Poisoning:

Background:

 

Tetrodotoxin is a potent heat stable neurotoxin found in certain pufferfish species. Ingestion of improperly prepared pufferfish can lead to severe poisoning. The tetrodotoxin binds to and blocks fast-gated sodium channels.

Clinical Manifestations:

 

Symptoms include rapid onset (30 min) of nausea, vomiting, paralysis, and respiratory failure. Death can occur within hours.

 

Clinical Management:

 

There is no specific antidote. Treatment involves supportive care, including respiratory support.

 

Clinical Disposition:

 

Admit (floor vs ICU depending on respiratory status)

Friedman MA et al. Ciguatera Fish Poisoning: Treatment, Prevention, and Management. Marine Drugs 2008; 6:456-479

Stratta P, Badino G. Scombroid poisoning. CMAJ. 2012 Apr 3;184(6):674. doi: 10.1503/cmaj.111031. Epub 2012 Jan 9. PMID: 22231690; PMCID: PMC3314039.

Kotipoyina HR, Kong EL, Warrington SJ. Tetrodotoxin Toxicity. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507714/


 ·